PL366039A1 - Antysensowne oligonukleotydy skierowane przeciw VR1 - Google Patents
Antysensowne oligonukleotydy skierowane przeciw VR1Info
- Publication number
- PL366039A1 PL366039A1 PL01366039A PL36603901A PL366039A1 PL 366039 A1 PL366039 A1 PL 366039A1 PL 01366039 A PL01366039 A PL 01366039A PL 36603901 A PL36603901 A PL 36603901A PL 366039 A1 PL366039 A1 PL 366039A1
- Authority
- PL
- Poland
- Prior art keywords
- antisense oligonucleotides
- oligonucleotides against
- nucleotide constructs
- pain
- substances
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2000143674 DE10043674A1 (de) | 2000-09-02 | 2000-09-02 | Antisense Oligonukleotide |
| DE10043702A DE10043702A1 (de) | 2000-09-04 | 2000-09-04 | Antisense Oligonukleotide |
| PCT/EP2001/010081 WO2002018407A2 (de) | 2000-09-02 | 2001-08-31 | Antisense oligonukleotide gegen vanilloid rezeptor 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366039A1 true PL366039A1 (pl) | 2005-01-24 |
Family
ID=26006931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01366039A PL366039A1 (pl) | 2000-09-02 | 2001-08-31 | Antysensowne oligonukleotydy skierowane przeciw VR1 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7662948B2 (pl) |
| EP (1) | EP1313768B1 (pl) |
| JP (1) | JP2004507263A (pl) |
| AT (1) | ATE385505T1 (pl) |
| AU (1) | AU2001295531A1 (pl) |
| CA (1) | CA2420656A1 (pl) |
| DE (1) | DE50113568D1 (pl) |
| ES (1) | ES2300366T3 (pl) |
| HU (1) | HUP0301805A3 (pl) |
| MX (1) | MXPA03001627A (pl) |
| NZ (1) | NZ524894A (pl) |
| PL (1) | PL366039A1 (pl) |
| WO (1) | WO2002018407A2 (pl) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105044A1 (en) * | 2001-10-17 | 2003-06-05 | Isis Pharmaceuticals Inc. | Antisense modulation of matrix metalloproteinase 1 expression |
| WO2003085110A2 (en) * | 2002-04-05 | 2003-10-16 | Santaris Pharma A/S | Oligomeric compounds for the modulation hif-1alpha expression |
| DE10322662A1 (de) * | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
| DE10257421A1 (de) * | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
| US20040115634A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Modulation of stat 6 expression |
| US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| EA014097B1 (ru) * | 2004-11-09 | 2010-08-30 | Сантарис Фарма А/С | ОЛИГОНУКЛЕОТИДЫ ЗАМКНУТОЙ НУКЛЕИНОВОЙ КИСЛОТЫ (LNA) ДЛЯ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HIF-1a И ИХ ПРИМЕНЕНИЕ |
| CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
| CA2739464C (en) * | 2008-10-03 | 2020-03-31 | Opko Curna, Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| MX2011005910A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. |
| CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| KR101682735B1 (ko) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | 뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료 |
| WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| CN102549159B (zh) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | 通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病 |
| KR101835889B1 (ko) | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료 |
| CA2761142C (en) | 2009-05-06 | 2021-06-08 | Opko Curna, Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| US9012139B2 (en) | 2009-05-08 | 2015-04-21 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family |
| DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
| WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
| CN103221541B (zh) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
| JP5944311B2 (ja) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療 |
| ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
| CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
| CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| US8572084B2 (en) * | 2009-07-28 | 2013-10-29 | Fti Consulting, Inc. | System and method for displaying relationships between electronically stored information to provide classification suggestions via nearest neighbor |
| WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
| EP2464731B1 (en) | 2009-08-11 | 2016-10-05 | CuRNA, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| EP2982755B1 (en) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| EP2470657B1 (en) | 2009-08-25 | 2019-10-23 | CuRNA, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| DK2480669T3 (en) | 2009-09-25 | 2018-02-12 | Curna Inc | TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY |
| CA2782366A1 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
| US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
| WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
| EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| RU2611186C2 (ru) | 2009-12-29 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63 |
| RU2016115782A (ru) | 2009-12-31 | 2018-11-28 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3) |
| US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
| WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
| EP2524039B1 (en) | 2010-01-11 | 2017-11-29 | CuRNA, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
| RU2611192C2 (ru) | 2010-01-25 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1 |
| KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(ｐｙｃｒ1)에 대한 천연 안티센스 전사체의 억제에 의한 ｐｙｃｒ1과 관련된 질환의 치료 |
| US8980856B2 (en) | 2010-04-02 | 2015-03-17 | Curna, Inc. | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
| RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
| RU2693462C2 (ru) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
| TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| JP5917497B2 (ja) | 2010-05-26 | 2016-05-18 | カッパーアールエヌエー，インコーポレイテッド | メチオニンスルホキシドレダクターゼａ（ｍｓｒａ）に対する天然アンチセンス転写物の阻害によるｍｓｒａ関連疾患の治療 |
| JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー，インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療 |
| JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー，インコーポレイテッド | Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療 |
| ES2640755T3 (es) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4 |
| EP2630241B1 (en) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
| US8987225B2 (en) | 2010-11-23 | 2015-03-24 | Curna, Inc. | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG |
| ES2653247T3 (es) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN |
| CN108272782B (zh) | 2011-09-06 | 2021-04-23 | 库尔纳公司 | 小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途 |
| US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| EP3126831A1 (en) | 2014-04-01 | 2017-02-08 | The Procter & Gamble Company | Method for screening trp channels |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| KR102620328B1 (ko) | 2014-10-03 | 2024-01-02 | 콜드스프링하버러보러토리 | 핵 유전자 산출량의 표적화 증강 |
| KR20220105174A (ko) | 2015-10-09 | 2022-07-26 | 유니버시티 오브 사우스앰톤 | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| WO2018081189A1 (en) | 2016-10-25 | 2018-05-03 | The Procter & Gamble Company | Fibrous structures |
| CA3037094C (en) | 2016-10-25 | 2021-12-28 | The Procter & Gamble Company | Fibrous structures |
| SG10202108375XA (en) | 2017-08-25 | 2021-09-29 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| US20230287410A1 (en) | 2020-05-11 | 2023-09-14 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6278038B1 (en) * | 1992-04-10 | 2001-08-21 | Oregon Health And Science University | Mammalian melanocortin receptors and uses |
| US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| FR2724934B1 (fr) * | 1994-09-26 | 1997-01-24 | Bio Merieux | Oligonucleotide chimere et son utilisation dans l'obtention de transcrits d'un acide nucleique |
| US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| EP1009804B1 (en) * | 1997-08-20 | 2003-10-29 | The Regents of the University of California | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
| AU2466799A (en) * | 1998-01-22 | 1999-08-09 | Regents Of The University Of California, The | Nucleic acid sequences encoding capsaicin receptors |
| EP0943683A1 (en) | 1998-03-10 | 1999-09-22 | Smithkline Beecham Plc | Human vanilloid receptor homologue Vanilrep1 |
| GB9822124D0 (en) * | 1998-10-09 | 1998-12-02 | Univ London | Ion channels |
| CA2348479A1 (en) * | 1998-11-13 | 2000-05-25 | Millennium Pharmaceuticals, Inc. | Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof |
| GB9826359D0 (en) | 1998-12-01 | 1999-01-27 | Glaxo Group Ltd | Novel receptors |
| GB9827016D0 (en) | 1998-12-08 | 1999-02-03 | Merck Sharp & Dohme | Receptor protein |
| EP1175504A4 (en) | 1999-04-15 | 2002-07-31 | Ortho Mcneil Pharm Inc | DNA WHICH CODES THE VANILLOID RECEPTOR VR1 |
| US6482611B1 (en) * | 1999-09-23 | 2002-11-19 | Neurogen Corporation | Human capsaicin receptor and uses thereof |
| US20040259092A1 (en) * | 2001-08-27 | 2004-12-23 | Carmen Barske | Nogo receptor homologues and their use |
-
2001
- 2001-08-31 DE DE50113568T patent/DE50113568D1/de not_active Expired - Lifetime
- 2001-08-31 CA CA002420656A patent/CA2420656A1/en not_active Abandoned
- 2001-08-31 AU AU2001295531A patent/AU2001295531A1/en not_active Abandoned
- 2001-08-31 MX MXPA03001627A patent/MXPA03001627A/es unknown
- 2001-08-31 NZ NZ524894A patent/NZ524894A/en unknown
- 2001-08-31 AT AT01976176T patent/ATE385505T1/de active
- 2001-08-31 WO PCT/EP2001/010081 patent/WO2002018407A2/de active IP Right Grant
- 2001-08-31 ES ES01976176T patent/ES2300366T3/es not_active Expired - Lifetime
- 2001-08-31 JP JP2002523921A patent/JP2004507263A/ja active Pending
- 2001-08-31 EP EP01976176A patent/EP1313768B1/de not_active Expired - Lifetime
- 2001-08-31 PL PL01366039A patent/PL366039A1/pl not_active Application Discontinuation
- 2001-08-31 HU HU0301805A patent/HUP0301805A3/hu unknown
-
2003
- 2003-03-03 US US10/376,341 patent/US7662948B2/en not_active Expired - Fee Related
-
2009
- 2009-12-23 US US12/645,625 patent/US20100316615A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004507263A (ja) | 2004-03-11 |
| HUP0301805A2 (hu) | 2003-08-28 |
| WO2002018407A9 (de) | 2003-05-15 |
| ES2300366T3 (es) | 2008-06-16 |
| US20100316615A1 (en) | 2010-12-16 |
| DE50113568D1 (de) | 2008-03-20 |
| CA2420656A1 (en) | 2003-02-26 |
| US20040002473A1 (en) | 2004-01-01 |
| WO2002018407A3 (de) | 2002-10-03 |
| MXPA03001627A (es) | 2003-06-24 |
| US7662948B2 (en) | 2010-02-16 |
| NZ524894A (en) | 2005-03-24 |
| WO2002018407A2 (de) | 2002-03-07 |
| EP1313768B1 (de) | 2008-02-06 |
| AU2001295531A1 (en) | 2002-03-13 |
| ATE385505T1 (de) | 2008-02-15 |
| HUP0301805A3 (en) | 2005-12-28 |
| EP1313768A2 (de) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03001627A (es) | Oligonucletodiso antisentido contra vr1. | |
| CA2296535A1 (en) | Antisense oligonucleotide inhibition of ras | |
| EP0957926A4 (en) | OLIGONUCLEOTIDE COMPOSITION AND METHOD FOR REGULATING THE PROTEIN B7 EXPRESSION | |
| EP1325019A4 (en) | ANTISENSE MODULATION OF CLUSTERIN EXPRESSION | |
| WO1999051731A3 (en) | Maize histone deacetylases and their use | |
| WO2001048190A3 (en) | Therapeutic uses of lna-modified oligonucleotides | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| HK1033278A1 (en) | Pharmaceutical preparation for use in anti-asthma therapy. | |
| DE69931029D1 (de) | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen | |
| WO2003106681A3 (de) | Antisense oligonukleotide gegen pim1 | |
| MX9801264A (es) | Control de la expresion del gen de cd44 para uso terapeutico. | |
| WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
| WO2002012338A3 (de) | Screeningverfahren | |
| HUP0202574A2 (en) | T cell receptor vbetha-dbetha-jbetha sequence and methods for its detection | |
| CA2495298A1 (en) | Use of antisense oligonucleotides to inhibit the expression of akt-1 | |
| DK1295611T3 (da) | Oligonukleotid-transformerende forbindelser | |
| WO2004013313A3 (en) | Antisense nucleic acids | |
| AU1138699A (en) | Dna demethylase, therapeutic and diagnostic uses thereof | |
| WO2005035549A3 (en) | Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier | |
| WO2004108898A3 (en) | Transfection agents | |
| AU2347501A (en) | Trp-protein-related mtr1 protein and dna sequence coding therefor | |
| WO2002101394A3 (de) | Screeningverfahren mit bnpi und dnpi | |
| PT980379E (pt) | Oligonucleotidos quimericos e sua utilizacao | |
| WO2002088665A3 (en) | Methods for identifying drugs specific for known molecular targets using model compounds specific for the molecular targets | |
| AU2739797A (en) | (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |